Seladelpar

Primary Biliary Cholangitis

Gilead SciencesSmall moleculePhase 3Active

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 89/ 100

Competitive context

18 Active assets in the Primary Biliary Cholangitis cohort.

Asset / Sponsor	Phase	Rating
Ursodeoxycholic Acid Xijing Hospital of Digestive Diseases	Phase 4	A
Saroglitazar Zydus Therapeutics Inc.	Phase 3	BB
Fenofibrate Xijing Hospital of Digestive Diseases	Phase 3	BB
Obeticholic Acid Intercept Pharmaceuticals	Phase 3	BB
cs0159 Cascade Pharmaceuticals, Inc	Phase 3	BB

View all 49 →

Same molecule, other indications

Seladelpar is also rated in:

hyperlipidemiaDormant

CCC

Indicative · Phase 2

54 / 100

primary sclerosing cholangitisDormant

CCC

Indicative · Phase 2

52 / 100

metabolic dysfunction-associated steatohepatitisDormant

CCC

Indicative · Phase 2

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.